ABL Completes Manufacture of Rhabdovirus-Based Oncolytic Therapeutic Vaccine for Phase I Clinical Trial

ABL Completes Manufacture of Rhabdovirus-Based Oncolytic Therapeutic Vaccine for Phase I Clinical Trial

  • November 6, 2013

ABL, Inc. (ABL) has successfully delivered the final dosage form of a Rhabdovirus-based oncolytic therapeutic vaccine to the Ottawa Hospital Research Institute (OHRI). OHRI contracted ABL to execute fill finish operations for its Rhabdovirus therapeutic vaccine including clinical labeling under current Good Manufacturing Practices (cGMPs) for use in human clinical trials.

The Rhabdovirus vaccine is a combination of a highly potent oncolytic virus with an immunologically active tumor associated antigen. Rhabdoviruses have been shown to effectively kill a wide variety of cancer cells, including cells from blood, breast, colon, ovarian, lung, and prostate cancers. Engineering of the Rhabdovirus resulted in a viral candidate with unique tumor-selecting mutations and the ability to express a tumor associated antigen. OHRI, Children’s Hospital of Eastern Ontario Research Institute (CHEO), and McMaster University have collaborated to create this novel Rhabdovirus oncolytic vaccine platform, which will be tested in a Phase I clinical trial.

Andrew Arrage, ABL’s Vice President of Business Development commented, “ABL has a long history of advancing breakthrough vaccines and therapies for its clients, providing effective solutions to often complex biomedical challenges. ABL’s cGMP virus and protein manufacturing capabilities, coupled with expanding clinical immunomonitoring services, provide our clients with needed solutions to their clinical manufacturing and testing needs.”

About ABL

ABL, Inc. is a Maryland-based biomedical contract research and manufacturing organization dedicated to advancing vaccines, therapeutics and other biologic products. ABL has extensive experience working with diverse organizations, including government and academic entities and commercial bio/pharmaceutical companies. Notable services include basic research, process and assay development, preclinical in vivo studies, in vitro laboratory services, clinical immunomonitoring, and Phase I/II cGMP biologics manufacturing. Since 2001, ABL has been a part of the Institut Mérieux, a group of companies dedicated to developing translational science for better patient care globally. For more information on ABL and our services, please visit our website at www.ablinc.com.

Contact:

ABL, Inc.

Andrew Arrage

Vice President, Business Development

301-816-5209

andrew.arrage@ablinc.com